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Abstract 
Objective: Gene–environment interactions contribute to the development of HIV-associated neurocognitive 
disorders. We examined whether childhood trauma, apolipoprotein E isoforms and viral protein R (Vpr) variants were 
associated with change in cognitive performance. Seventy-three seropositive women completed neuropsychological 
assessments at baseline and 1-year follow-up. We conducted genetic analyses using DNA obtained from blood and 
calculated risk scores based on Vpr amino acid 37, 41 and 55 variants that were previously associated with cognitive 
performance.
Results: Global cognitive scores declined significantly over the 1-year study period (p = 0.029). A reduction in global 
cognitive scores was associated with childhood trauma experience (p = 0.039).
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Introduction
HIV-associated neurocognitive disorders (HAND) 
describe a spectrum of cognitive, behavioural and motor 
disturbances that may occur secondary to HIV infec-
tion [1]. Though improvement in and increased access 
to antiretroviral therapy (ART) has reduced the severity 
of HAND, milder forms persist and may affect up to 50% 
of the estimated 36.9 million people infected with HIV 
worldwide [1–3]. There is thus a need to identify genetic 
and environmental factors that increase the risk of devel-
oping HAND.
Genetic variation in the gene encoding apolipoprotein 
E (ApoE) has been suggested to contribute to HAND 
[4–6]. Two single nucleotide polymorphisms (rs7412 
and rs429358) that encode C/T transitions give rise to 
cysteine/arginine amino acids at residue positions 112 
and 158, the combination of which designates three iso-
forms i.e. ApoE ε2, ε3 and ε4 [7]. This genetic variation, 
specifically the ε4 isoform, may affect HIV infection [8] 
and replication in the brain [9], as well as susceptibility 
to HIV-related neurotoxic proteins [10]. Viral genetic 
variation may also contribute to HAND, with a study by 
Dampier et  al. [11] identifying three amino acids (AAs) 
in viral protein R (Vpr) that affect neurocognitive perfor-
mance. This 96-AA accessory protein plays a role in HIV 
infection and viral transcription, and may contribute to 
neuronal apoptosis, synaptic loss, proinflammatory sig-
nalling, oxidative stress and blood–brain barrier perme-
ability [12–17]. Childhood trauma (CT) occurs during 
a period of rapid neurodevelopment and maturation, 
potentially exerting long-term consequences on neuro-
biology and mental health [18, 19]. Accordingly, CT has 
been identified as a predictor of poorer cognitive perfor-
mance in women living with HIV [20–22].
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The aetiology of HAND is complex and multifactorial. 
We examined the associative and interactive effects of 
CT and variation in ApoE and Vpr on cognitive function 
over a 1-year period in a cohort of South African women 
living with HIV.
Main text
Methods
Study design and participants
This was a nested study of an investigation of the bio-
logical endophenotypes of HIV and CT. Seventy-three 
women who met the study inclusion criteria [20] were 
recruited from community health care centres in Cape 
Town between 2008 and 2016. The study was approved 
by the Stellenbosch University Health Research Ethics 
Committee and written informed consent was obtained 
from all participants.
Clinical assessments
Participants provided sociodemographic data and were 
assessed for the presence of psychiatric disorders with 
the MINI-International Neuropsychiatric Interview-Plus 
[23]. Neurocognitive testing was done at baseline and 
1-year with the HIV Neurobehavioral Research Center 
Neuropsychological (NP) battery [24], which taps into 
seven domains of cognitive function: motor ability, pro-
cessing speed, verbal fluency, learning, delayed recall, 
attention/working memory and executive function. Raw 
scores from the seventeen NP tests were used to gen-
erate an age- and education-adjusted global cognitive 
z-score [20]. The 28-item Childhood Trauma Question-
naire-Short Form (CTQ-SF) was administered at base-
line to assess for CT experienced prior to 18 years of age 
[25]. HIV infection was confirmed using enzyme-linked 
immunosorbent assays.
Apolipoprotein E genotyping
Genotyping for ApoE was performed as previously 
described [6]. DNA extracted from whole blood was 
subjected to  KASP® genotyping technology (LGC, 
Middelsex, UK) for the two ApoE variants rs7412 and 
rs429358. Genotyping was successfully undertaken for 62 
participants.
Viral protein R amino acid assessment
Polymerase chain reaction (PCR) using DNA obtained 
from whole blood at 1-year follow-up and primers 
(Integrated DNA Technologies, Coralville, IO) flanking 
the region of interest was performed, and the resulting 
amplicons were cleaned using the Wizard SV Gel and 
PCR Clean-up System (Promega, Fitchburg, WI). Eluted 
samples were subjected to a sequencing PCR reaction 
using the BigDye Terminator v3.1 Cycle Sequencing 
kit (Applied Biosystems, Carlsbad, CA) and automated 
Sanger sequencing was performed on the 3130 × L 
Genetic Analyser (Applied Biosystems, Carlsbad, CA). 
Sequences were manually quality checked and assembled 
using Sequencher 5.4.6 (Gene Code Corporation, Ann 
Arbor, MI) with a minimum overlap of 1 and a minimum 
match of 60. Sequences were aligned and trimmed to 
contain Vpr bases using Geneious version 10.1.3 (Biomat-
ters, Auckland, New Zealand). The trimmed sequences 
were submitted to Los Alamos National Laboratory for 
quality control and initial subtyping. Sequence subtyp-
ing was conducted using four online tools: Context-based 
Modelling for Expeditious Typing HIV-1 [26], jumping 
profile Hidden Markov Models [27], REGA HIV Subtyp-
ing Tool version 3 [28] and Recombinant Identification 
Program [29]. Vpr AA identification was successfully per-
formed for 66 participants.
Statistical analyses
Demographic and clinical characteristics according to 
CT exposure (CTQ-SF score > 40 indicative of at least 
mild-to-moderate CT exposure) were assessed using 
Student’s t-tests, Mann–Whitney U tests or Pearson Chi 
square tests. As viral load data were highly skewed, we 
generated log-transformed data for subsequent analy-
ses. Genotyping results were used to classify participants 
according to the presence of the ε4 isoform i.e. hetero- 
and homozygous individuals were grouped. We classified 
AAs according to their effects on cognition, as reported 
by Dampier et  al. [11], with higher scores indicative of 
greater risk. Accordingly, the AAs were scored as follows: 
AA37 I (neuroprotective) variant = 0, other (neutral) 
variants = 1; AA41 S (neuroprotective) variant = 0, N 
(risk) variant = 2, other (neutral) variants = 1; and AA55 
A (risk) variant = 1, other (neutral) variants = 0. A com-
posite risk score was generated by summing the values 
assigned to the three AAs. Repeated measures analyses 
with 1-year global cognitive score as the outcome meas-
ure, baseline global cognitive score as a predictor and 
continuous CTQ-SF scores, ApoE ε4 carrier status, and 
individual and composite AA risk scores as between sub-
ject factors in regression models were performed. We 
examined whether including interactions between pre-
dictor variables explained more of the variation in our 
data by using ANOVA to compare the fit of the models 
produced using factors or factors plus their interaction 
effects. As CD4 and CD8 lymphocyte counts, as well as 
both original and log-transformed viral load values were 
not associated with global cognitive scores, these param-
eters were not included as covariates. All statistical analy-
ses were performed in R [30] and an alpha value of less 
than 0.05 was deemed statistically significant.
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Results
Demographic and clinical characteristics
Neurocognitive assessments at baseline and follow-up 
were completed by 73 women (mean age 35.23  years) 
who self-identified as “Black, isiXhosa-speaking”. 
Approximately three-quarters of the sample (76.7%) 
were on ART. Based on the 63 women who provided 
their year of diagnosis, the mean time since confirmed 
HIV infection was 13.13  years. A repeated measures 
t test comparing global cognitive scores at baseline 
(mean = − 0.02, standard deviation = 0.55) and follow-
up (mean = − 0.12, standard deviation = 0.53) indicated 
a significant decline in cognitive scores over the 1-year 
study period (t(72) = 2.22, p = 0.029). Most participants 
(n = 54, 74%) self-reported CT of at least low-to-mod-
erate severity (CTQ-SF ≥ 41). Participants who expe-
rienced CT were more likely to be on ART (p = 0.001) 
and showed trends towards a lower median level of edu-
cation (p = 0.052) and lower follow-up global cognitive 
score (p = 0.064). Our assessment of viral load was lim-
ited to the 38 individuals (15 without CT and 23 with 
CT) with a viral load above the detectable level i.e. ≥ 40 
copies/ml. Only analyses that used the original data 
indicated significantly higher viral loads in participants 
with CT exposure (p = 0.023). Demographic and clini-
cal data are summarised in Table 1. The CTQ-SF scores 
ranged from 25 to 114 and were used to categorise par-
ticipants based on the severity of CT exposure (Table 2). 
Table 1 Baseline demographic and clinical characteristics of study participants by childhood trauma exposure
AA amino acid, ApoE apoliprotein E, ART antiretroviral therapy, SD standard deviation
Parametric and non-parametric data are represented as mean ± SD and median and interquartile range respectively
a Viral load comparisons included the 38 participants with a viral load of greater than or equal to 40, the lower limit of sensitivity of the assay
b Amino acid data was available for 66 participants
c ApoE ε4 allele comparison included the 63 participants for whom genotype information was available
All participants (n = 73) Childhood trauma (n = 54) No childhood trauma 
(n = 19)
t U χ2 P
Mean age in years ± SD 35.23 ± 7.24 35.81 ± 6.60 33.58 ± 8.80) –1.16 0.250
Median years of education 
(interquartile range)
11.00 (9.00 –11.00) 10.00 (9.00 –11.00) 11.00 (10.00–12.00) 362.00 0.052
Median viral load (interquar-
tile range)a
18,459.50 (1732.25–
64,831.75)
24,510.00 (4478.00–
64,634.50)
9759.00 (1284.50–50,905.50) 320.50 0.023
Median log-transformed 
viral load (interquartile 
range)a
4.26 (3.20 –4.82) 4.39 (3.52 –4.81) 3.99 (3.08–4.87) 140.00 0.332
Median CD4 count (inter-
quartile range)
453.00 (270.50–664.25) 432.00 (259.50–643.75) 481.50 (410.25–677.75) 412.00 0.336
Median CD8 count (range) 834.00 (620.50–1107.75) 768.00 (539.00–1090.00) 1050.00 (754.00–1284.00) 357.50 0.203
On ART treatment 56 47 9 12.38 0.001
AA37 b 1.11 0.574
I 3 3 0
AA41b 2.78 0.427
S 24 20 4
N 12 7 5
AA55b 5.61 0.061
A 13 13 0
Hetero- or homozygous for 
the ApoE ε4  allelec
26 18 8 1.72 0.190
Mean baseline global cogni-
tive score ± SD
–0.02 ± 0.55 –0.08 ± 0.54 0.15 ± 0.53 1.61 0.112
Mean follow-up global 
cognitive score ± SD
–0.12 ± 0.53 –0.19 ± 0.55 0.07 ± 0.41 1.88 0.064
Table 2 Participants categorisation by  childhood trauma 
severity
CTQ-SF Childhood Trauma Questionnaire-Short Form
None 
or minimal 
CTQ-SF ≤ 40
Low-to-moderate 
41 ≤ CTQ-SF ≤ 55
Moderate-
to-severe 
56 ≤ CTQ-SF ≤ 72
Severe-to-
extreme 
73 ≤ CTQ-SF
Number of 
par-
ticipants 
(%)
19 (26.0) 10 (13.7) 17 (23.3) 27 (37.0)
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Change in global cognitive score analyses
Repeated measures analyses indicated that CTQ-SF score 
was significantly associated with decreased global cogni-
tive scores over the 1-year study period with each unit 
increase in CTQ-SF score associated with a 3.88 × 10− 3 
decrease in global cognitive score (p = 0.039) (Fig. 1). No 
significant effects of ApoE isoform or AA risk variants 
on global cognitive function were found. Test statistics 
for study variables are summarised in Additional file  1: 
Table  S1. Comparing model fit revealed that including 
the interactive effects of ApoE4, CT, AA41 and AA55 
explained significantly more of the variance in cognitive 
function (Akaike information criterion reduced from 
56.28 to 54.69, p = 0.042). Factor interaction effects on 
model fit are summarised in Additional file 2: Table S2.
Discussion
Our study examined the contribution of variation in 
ApoE and Vpr to change in cognitive function over time 
in a unique cohort of South African women with varia-
ble exposure to CT. In keeping with previous studies, we 
found that CT experience was associated with a decline 
in global cognitive scores over the course of one year 
[20, 21]. Though the estimated effect of CTQ-SF score 
on global cognitive score was small, it is possible that the 
influence of high CT exposure acting over a prolonged 
period may produce clinically meaningful effects. Draw-
ing on the findings of Dampier et al. [11], we generated 
risk scores based on Vpr AA variation. Our analyses 
indicated that including the interactive effects of ApoE, 
CTQ score and AA41 and AA55 risk variants explained 
significantly more of the variance in global cognitive 
scores over the 1-year study period. Such higher order 
interactive effects may be due to common pathophysi-
ological mechanisms shared by these factors, such as 
inflammation, oxidative stress, and altered synaptic plas-
ticity and glucocorticoid signalling, which are implicated 
in HAND pathogenesis [15, 16, 31–39]. These factors 
may interact to facilitate disease progression. For exam-
ple, Vpr influences both host and viral gene transcrip-
tion through its role as a coactivator of glucocorticoid 
receptors [40]. Thus, CT-induced changes to glucocorti-
coid receptor mRNA expression may in turn affect HIV 
pathophysiology through a Vpr-dependent mechanism 
[41]. The ApoE ε4 isoform has been suggested to mediate 
the effects of CT on later life mental health and cogni-
tion [42, 43]. Finally, both AA41 and AA55 are included 
in the second alpha helix of Vpr, a region of the protein 
associated with activation of viral transcription as well as 
cellular apoptosis, both of which are likely important in 
HIV-related neuropathogenesis [44]. Though our results 
are in keeping with the multifactorial aetiology of HAND, 
Fig. 1 Childhood trauma was significantly associated with decreased global cognitive scores over the 1-year study period. Each unit increase in 
CTQ-SF score was associated with a 3.88  ×  10− 3 decrease in global cognitive score (p = 0.039)
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further studies in larger sample sizes will be required to 
unpack these interactions, determine their effect size and 
ultimately their clinical significance.
Limitations
The NP battery provides information on seven cognitive 
domains and thus our use of a global score will not reveal 
domain-specific effects. Though we found a reduction in 
cognitive scores over one year, the clinical significance of 
this decline is uncertain as both baseline and follow-up 
cognitive scores were within normal range. Neverthe-
less, the drop in scores is concerning considering that 
most women were on ART. Several confounding fac-
tors potentially affect CT measurement. As a retrospec-
tive self-report measure, the CTQ-SF may be influenced 
by subjective factors such as memory and recall bias 
[45]. We used the CTQ-SF total score in our regression 
models and therefore cannot determine whether specific 
subtypes of CT produce differential effects on cognitive 
performance. It is possible that additional covariates not 
included in our study, such as HIV-related comorbidi-
ties, may affect cognitive scores. Our findings are also 
not necessarily applicable to men. We grouped individu-
als hetero- and homozygous for the ε4 isoform, and thus 
cannot determine whether dose–response effects could 
influence global cognitive scores. Finally, our relatively 
small sample size may be insufficient to identify rela-
tionships between our predictor variables and change in 
cognitive function, especially given the rarity of certain 
genetic variants, such as AA37 I, in our study group.
Nevertheless, these findings support the influence of CT 
on neurocognitive function and suggest that host and viral 
genetic factors interact to influence cognitive function in 
HIV. This study has several strengths. We used longitudinal 
data, an important consideration in examining the develop-
ment of disorders. Our study was conducted in a popula-
tion that is disproportionately affected by HIV. Females 
comprise the majority of the approximately 7.52 million 
seropositive individuals in South Africa [46]. Furthermore, 
CT is common in South Africa, including among people 
living with HIV [47, 48]. We suggest future studies explore 
the contributions of ApoE, Vpr and CT to HAND, using 
larger sample sizes, which include both men and women.
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